Key result
Low molecular weight heparin provides effective bridging therapy during temporary anticoagulation interruptions.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
F.W.A. Verheugt; Low molecular weight heparin: a bridge over troubled water, European Heart Journal, Volume 23, Issue 15, 1 August 2002, Pages 1144–1146, h
No takes yet. Share an insight, caveat, or question.
Freek W.A. Verheugt (2002) studied this question. Low molecular weight heparin serves as a bridging therapy strategy for cardiovascular patients requiring temporary anticoagulation management.
Synapse has enriched 10 related papers. Consider them for comparative context: